Reading a trial

Cinnamon At Two Grams A Day: What The Pooled Trials Actually Used

Rolled quills of cinnamon bark lie across the front of the seller's marketing panel, the easiest of the six pictured plants to name on sight. Cinnamon is also the most-studied spice in the metabolic supplement category, with the deepest human trial record of anything pictured on that panel — and a second figure, about the same bark, that matters just as much and gets mentioned far less often.

By Vinetaro Drops Team · Last updated September 26, 2026 · 11 min read · Reading a trial

The most recognisable plant on the panel

The ingredients page on this website sets out what the Vinetaro Drops bottle prints on its front label: a brand, a product name, a marketing line, three support phrases and a volume, with no ingredient named anywhere and no back-label photograph among the images the seller supplies. A separate marketing panel arranges six plants around the bottle instead, uncaptioned, and cinnamon bark is the easiest of the six to identify on sight — rolled quills of inner bark are unmistakable at any resolution, unlike the dried flowers or the small red berry elsewhere on the same panel.

Being easy to name is not the same as being present in a measured amount, and this article treats the photograph exactly the way every other article on this blog treats one: as marketing artwork, not a supplement panel. What makes cinnamon worth a full article on its own is that, unlike most of what is photographed on this panel, cinnamon's human trial record in the metabolic category is unusually deep, recent, and specific about dose.

Two species, one common name

“Cinnamon” on a label or in a photograph can refer to either of two botanically distinct barks. Cassia cinnamon (Cinnamomum cassia, sometimes labelled Cinnamomum aromaticum) is the darker, stronger-flavoured bark sold in most supermarkets and used in the large majority of the trials discussed below. Ceylon cinnamon (Cinnamomum verum) is a lighter, more delicate bark, more expensive, and considerably lower in the compound at the centre of the safety question further down this page.

A photograph cannot distinguish the two species, and neither can most consumers without training. That distinction matters for exactly the reason species-level naming matters throughout this blog: two products both honestly photographed as “cinnamon” can differ meaningfully in what they deliver.

The 2024 dose-response analysis: 24 trials pooled

A 2024 updated systematic review and dose-response meta-analysis pooled 24 randomised controlled trials examining cinnamon supplementation and glycaemic control in people with type 2 diabetes. The analysis reported fasting glucose and HbA1c, the standard three-month average blood sugar marker, falling with cinnamon supplementation across the pooled trials, while fasting insulin did not show a significant change. A dose-response design is a more demanding analysis than a simple pooled average: it specifically tests whether a larger dose produced a larger effect, which is a more useful question for anyone trying to work out what amount actually matters.

The fact that glucose and HbA1c moved while insulin did not is a meaningful detail rather than a footnote. It suggests, without proving, a mechanism that does not primarily run through increased insulin secretion — consistent with proposed actions like slowed carbohydrate digestion or improved insulin sensitivity at the tissue level, though the human evidence for the exact mechanism remains thinner than the evidence for the glucose and HbA1c outcomes themselves.

What the Cochrane review adds

An earlier Cochrane review pooled the trials available to it at the time and found a broadly similar direction, with the trials it reviewed using a mean of roughly 2 grams of cinnamon a day, mostly Cinnamomum cassia, for periods running from 4 to 16 weeks. Two grams is a level teaspoon of ground cinnamon, taken daily, for one to four months — a quantity anyone can picture from a kitchen spice rack, which is part of why cinnamon is such an approachable subject for this kind of dose comparison.

Two grams a day is the reference point worth carrying forward: a level teaspoon, taken daily, for weeks at a time, in trials that reported the actual dose used.

The coumarin ceiling: 7 mg a day for a 70 kg adult

A dose figure is only half of a safety picture, and cinnamon carries a second number worth knowing that has nothing to do with how much is needed for an effect and everything to do with how much is safe to take regularly. Cassia cinnamon naturally contains coumarin, a compound that in concentrated, repeated exposure has been linked to liver effects in sensitive individuals.

A formal toxicology and risk assessment of coumarin, drawing on human data, is the basis for a European-set tolerable daily intake of 0.1 mg of coumarin per kilogram of body weight — which works out to roughly 7 mg of coumarin a day for a 70 kg adult. Ceylon cinnamon contains only trace coumarin by comparison and is not the practical concern; cassia cinnamon, the variety in most supermarket jars and most inexpensive supplements, is where the ceiling becomes relevant at higher, sustained daily doses.

Who was in the trials, and why it matters

Every trial referenced above ran in adults already diagnosed with type 2 diabetes, under some degree of clinical supervision. That is a different starting point from a healthy adult without a diabetes diagnosis reaching for a wellness product, for the same reason this distinction matters throughout this blog: a measurable effect requires room to move, and a diagnosed metabolic condition provides more of that room than a healthy baseline does. A result in that population does not automatically describe what, if anything, happens in a healthy one, and none of the trials above were designed to answer that separate question.

1. Ask who was in the trial before assuming a result applies broadly.
2. A diagnosed population and a healthy population are not interchangeable audiences for the same intervention.
3. Supervision, monitoring and dose accuracy in a clinical trial are better than they will be from a kitchen spice jar.
4. None of this makes cinnamon's studied effect untrue. It makes it specific, in the way a good result usually is.

What transfers to this bottle, and what does not

Nothing above can be attributed to the bottle sold on this website. The label names no ingredient, states no plant part or species, gives no extract ratio, and prints no amount. Cinnamon appearing on a marketing photograph establishes only that a photograph of cinnamon quills was chosen for the artwork.

Every field the trials supply, this label leaves blank. Cinnamon's evidence base is genuinely stronger than most of what this category relies on, which makes the gap between that evidence and an unlabelled bottle worth stating plainly rather than glossing over because the underlying research happens to be good.

A practical way to read cinnamon claims elsewhere

Because cinnamon is inexpensive, familiar and easy to add to food, it shows up in supplement blends far more often than most of the botanicals covered on this blog. The checklist below applies whether the product being compared is this one or a competitor's.

• Look for a stated species: cassia or verum. A label that says only “cinnamon” has not answered this.
• Look for a milligram figure per serving, not folded into a blend total. “Contains cinnamon” inside a 200 mg proprietary blend is not comparable to 2 grams on its own line.
• If the figure is close to or above a few grams a day and the species is cassia, ask whether a coumarin figure has been disclosed, since the tolerable daily intake sits around 7 mg for a 70 kg adult.
• Treat a photograph of bark or quills on packaging as artwork, the same way this article treats the one on this product's own marketing panel.

None of this proves the bottle sold on this website does or does not contain cinnamon at any dose. It cannot, because the label names no ingredient. What it does is give a reader the comparison that is actually available: a level teaspoon a day, in trials that ran for weeks in a diagnosed population, against a photograph with no amount printed anywhere near it.

References